Fortune Business Insights foresees the pharmaceutical segment to dominate the global epigenomics market on account of the increasing prevalence of chronic diseases such as cancer. According to the World Health Organization (WHO), by the end of 2025, the number of cancer patients will reach 21,471,996.
Some of the major companies that are present in the Global Epigenomics Market
- Novartis AG
- Abbott Laboratories
- Abcam plc
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Zymo Research Corporation
- Illumina Inc.
- Agilent Technologies Inc
- Epizyme Inc.
- Boehringer Ingelheim International GmbH
- Bayer AG
- Epigenomics and other players.
Upgraded Therapeutic Procedures to Fuel Demand for Epigenomics in Market
Geographically, the global epigenomics market is anticipated to be dominated by North America owing to the presence of better healthcare infrastructure and proper medical facilities. Besides this, the availability of upgraded therapeutic machinery and supportive reimbursement policies for people, especially in developed nations such as Canada and the U.S. are also helping the market in the region gain dominance and continue dominating in the years to come.
Asia Pacific, on the other hand is prognosticated to show faster growth rates on account of increasing disposable income of people and introduction and implementation of advanced technology in medical technology and treatment facilities. The developing nations are trying to impose new medication therapies for better outcomes.
The increasing demand for personalized medicines is boosting the market for DNA methylation. Market vendors are focusing on company collaborations, mergers and acquisitions, and other strategies in order to stay at the top of the market. Major companies operating in the global epigenomics market are Abbott Laboratories, Boehringer Ingelheim International GmbH, Agilent Technologies Inc., Bayer AG, Thermo Fisher Scientific Inc., Epizyme Inc., Abcam plc, Zymo Research Corporation, Merck KGaA, Epigenomics, Illumina Inc., and Novartis AG.
More Trending Topics From Fortune Business [email protected]